Skip to main content

Table 3 Treatment compliance

From: Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience

  n = 169 cycles
  No. %
Delay 1st day   
   1–8 days 3 1.8
   9–15 days 3 1.8
   > 15 days 1 0.6
Delay 6th day   
   +1 11 6.5
   +2 8 4.7
   +3 5 3.0
   > +3 4 2.4
  n = 169 cycles
  No. %
Dose reduction of all drugs   
   ≤ 25% 18 10.6
   26–50% 5 3.0
   > 50% 0 0
Dose reduction of only A-T   
   ≤ 25% 3 1.8
   26–50% 4 2.4
   > 50% 0 0
Dose reduction of only GEM   
   ≤ 25% 2 1.2
   26–50% 7 4.1
   > 50% 0 0
  1. A, doxorubicin; T, paclitaxel; GEM, gemcitabine